Federal Circuit appeals
The United States Court of Appeals for the Federal Circuit holds exclusive jurisdiction over appeals in patent cases. Created in 1982 by the Federal Courts Improvement Act, the court reviews final judgments from district courts in patent cases, decisions of the Patent Trial and Appeal Board, and final determinations of the U.S. International Trade Commission. The standard of review on each issue varies: legal questions are reviewed de novo, factual findings for clear error or substantial evidence, and discretionary calls for abuse of discretion.
The rule
Under 28 U.S.C. § 1295(a), the Federal Circuit has exclusive jurisdiction over: appeals from final decisions of district courts where the action arises in whole or in part under any Act of Congress relating to patents (§ 1295(a)(1)); appeals from decisions of the Patent Trial and Appeal Board with respect to patent applications, reexaminations, and post-grant proceedings (§ 1295(a)(4)(A)); and appeals from final determinations of the U.S. International Trade Commission relating to unfair practices in import trade under § 337 of the Tariff Act of 1930 (§ 1295(a)(6)). The court also reviews various other matters — government contract claims, claims against the United States in the Court of Federal Claims, certain trademark and veterans matters — but its patent docket is the source of its centrality to the patent system.
Congress created the court in 1982 to centralize patent appeals and bring uniformity to the patent law that had previously been scattered across the regional circuits. The court applies its own precedent on patent issues; on issues of regional circuit law (for example, transfer under § 1404(a)), it applies the law of the regional circuit in which the district court sits.
Governing statutes and rules
- 28 U.S.C. § 1295 — exclusive Federal Circuit jurisdiction.
- 28 U.S.C. § 2107 — time for appeal in civil cases (incorporated by FRAP 4).
- Fed. R. App. P. 3 — manner of taking an appeal.
- Fed. R. App. P. 4(a) — thirty-day deadline to file notice of appeal in civil cases (sixty days where the United States is a party).
- Fed. R. App. P. 28, 32 — content and form of briefs.
- Fed. R. App. P. 35, 40 — en banc review and panel rehearing.
- Federal Circuit Rules — local rules supplementing the FRAP, including filing requirements, page limits, and confidentiality procedures.
- 5 U.S.C. § 706 — substantial evidence standard for review of agency decisions, including PTAB and ITC.
The framework: notice to mandate
Notice of appeal
An appeal from a district court is taken by filing a notice of appeal in the district court within thirty days of the judgment (sixty days if the United States is a party). Fed. R. App. P. 4(a)(1). Certain post-judgment motions — for example, a Rule 50, 52, or 59 motion — toll the appeal period. Fed. R. App. P. 4(a)(4). The deadline is jurisdictional. Bowles v. Russell, 551 U.S. 205 (2007).
An appeal from the PTAB is taken by filing a notice of appeal with the Director of the USPTO within sixty-three days of the Board's final decision (35 U.S.C. § 142; 37 C.F.R. § 90.3). An appeal from the ITC is taken by filing a petition for review in the Federal Circuit within sixty days of the final determination (28 U.S.C. § 2344; 19 U.S.C. § 1337(c)).
Docketing and briefing
Once docketed, the appellant pays the docketing fee, files a docketing statement, and orders the transcript. The Federal Circuit Mediation Program offers an opportunity for early settlement. The briefing schedule begins with the principal brief by the appellant (typically due forty days after the certified list or appendix is filed for PTAB appeals), followed by the appellee's brief, the reply, and the joint appendix. Briefs are subject to word limits under FRAP 32 (currently 13,000 words for principal briefs and 6,500 for reply briefs).
Oral argument
Oral argument is generally granted in patent appeals where the case is non-frivolous and turns on a contested issue. Argument is typically fifteen minutes per side, before a three-judge panel. The court issues most opinions within three to nine months of argument.
Standards of review
The applicable standard depends on the issue:
- Legal questions — de novo. Including statutory interpretation, the ultimate construction of patent claims, the legal conclusion of obviousness, definiteness, and patent eligibility under § 101.
- Subsidiary factual findings on claim construction — clear error. Following Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 574 U.S. 318 (2015), subsidiary findings about the meaning of technical terms to a person of ordinary skill, where based on extrinsic evidence, are reviewed for clear error under Fed. R. Civ. P. 52(a)(6). Where construction rests on intrinsic evidence alone, review remains de novo.
- Jury findings — substantial evidence. Including infringement, anticipation, the underlying factual findings in obviousness, willfulness as a factual matter, and damages.
- Bench-trial findings — clear error. Including findings on inequitable conduct (after Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir. 2011) (en banc)) and findings on damages.
- Discretionary rulings — abuse of discretion. Including evidentiary rulings, discovery sanctions, attorney fees under 35 U.S.C. § 285 (Highmark Inc. v. Allcare Health Management System, Inc., 572 U.S. 559 (2014)), enhanced damages under § 284 (Halo Electronics, Inc. v. Pulse Electronics, Inc., 579 U.S. 93 (2016)), and the grant or denial of injunctive relief under eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006).
- Agency decisions — substantial evidence on factual findings, abuse of discretion on procedural choices, de novo on questions of law. 5 U.S.C. § 706. The PTAB's factual findings on anticipation and on motivation to combine for obviousness are reviewed for substantial evidence. In re Gartside, 203 F.3d 1305 (Fed. Cir. 2000).
For a fuller treatment, see standards of review.
Mandate
The mandate issues seven days after the time to file a petition for rehearing has expired or, if a petition is filed, after the panel disposes of it. Fed. R. App. P. 41(b). The mandate transfers jurisdiction back to the district court or agency.
Burden, timing, and key deadlines
The appellant bears the burden of showing reversible error. The appellee may defend the judgment on any ground supported by the record.
Typical patent appeal timeline:
- Day 0: Final judgment in the district court (or final agency decision).
- Day 28–63: Notice of appeal (deadline depends on party and forum).
- ~Day 90–150: Joint appendix and opening brief.
- ~Day 150–210: Appellee's brief.
- ~Day 200–240: Reply brief.
- ~Day 270–540: Oral argument.
- ~Day 360–730: Decision.
Median time from notice of appeal to disposition for the Federal Circuit's patent docket has historically run about thirteen to fifteen months.
Petition for rehearing and en banc review
A petition for panel rehearing or rehearing en banc must be filed within forty-five days of the panel decision in cases involving the United States and within fourteen days otherwise. Fed. R. App. P. 35(c), 40(a)(1); Fed. Cir. R. 35, 40. En banc rehearing is rare and is typically granted only where the case raises a question of exceptional importance, where panel decisions are inconsistent, or where the panel has departed from established precedent. Recent en banc decisions of consequence include Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (en banc); Therasense, 649 F.3d 1276 (Fed. Cir. 2011); Suprema, Inc. v. ITC, 796 F.3d 1338 (Fed. Cir. 2015) (en banc); and Williamson v. Citrix Online, LLC, 792 F.3d 1339 (Fed. Cir. 2015) (en banc).
Petition for certiorari
A petition for a writ of certiorari to the Supreme Court must be filed within ninety days of entry of the Federal Circuit's judgment (or denial of rehearing). Sup. Ct. R. 13. The Supreme Court has actively reviewed the Federal Circuit's patent jurisprudence in cases such as KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007), eBay, Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014), Octane Fitness, LLC v. ICON Health & Fitness, Inc., 572 U.S. 545 (2014), Halo, TC Heartland, and Teva.
Interaction with related procedural mechanisms
Mandamus
Outside of final-judgment appeals, the Federal Circuit reviews interlocutory venue and transfer orders by mandamus. The standard is demanding — clear abuse of discretion producing a patently erroneous result — but the court has used mandamus actively in venue cases. See patent venue.
Stays pending appeal
A district court may stay execution of judgment, including injunctive relief, pending appeal under Fed. R. Civ. P. 62. Where the district court denies a stay, the appellant may apply to the Federal Circuit under Fed. R. App. P. 8. The four-factor stay standard from Hilton v. Braunskill, 481 U.S. 770 (1987), governs.
Cross-appeals and conditional cross-appeals
An appellee that seeks to enlarge its rights under the judgment must file a cross-appeal. The Federal Circuit has been strict in distinguishing arguments to defend the judgment (no cross-appeal needed) from arguments to alter it (cross-appeal required).
PTAB appeals and Article III standing
An IPR petitioner that loses at the Board may appeal only if it has Article III standing. Consumer Watchdog v. Wisconsin Alumni Research Foundation, 753 F.3d 1258 (Fed. Cir. 2014); Phigenix, Inc. v. Immunex Corp., 845 F.3d 1168 (Fed. Cir. 2017). The patent owner generally has standing to appeal an adverse Board decision because the cancellation of claims is a concrete injury. See standing.
Joinder of related appeals
The Federal Circuit routinely consolidates related district court and PTAB appeals, particularly where the same patent is at issue in multiple proceedings.
Practical notes
Preserve every issue
Federal Circuit review depends on what was preserved below. File the appropriate Rule 50, 51, and 52 motions; object to jury instructions; and ensure that critical evidence is in the record. The court will not review issues raised for the first time on appeal absent extraordinary circumstances.
Pick the standard of review carefully
An appellant who frames a question as legal (de novo) when the district court found facts will lose credibility. An appellant who concedes "clear error" when the question is a pure matter of law forfeits leverage. The opening brief should articulate the correct standard for each issue.
Mind the joint appendix
The joint appendix must contain everything the panel will need. Pages omitted from the appendix are effectively unavailable on appeal, even if they are in the district court record.
Pre-argue strategically
Federal Circuit oral argument is short. Open with the strongest narrow point that wins the case; do not save it for rebuttal. Be ready for a rapid colloquy on the panel's questions about claim language, record citations, and standard of review.
Watch for amicus interest
The Federal Circuit's patent docket attracts substantial amicus participation. Coordinate with potential amici early, and ensure the principal brief leaves room for amici to develop angles the parties cannot.
Consider the PTAB record
Where the same patent is in litigation at the PTAB and in district court, ensure that the PTAB record will be available for cross-reference at the Federal Circuit. Estoppel, claim construction, and prior art rulings move between the two tracks.
Pressure points
Teva and the limits of factual deference
Ten years after Teva, the Federal Circuit continues to debate which subsidiary findings in claim construction merit clear-error deference and which collapse back into de novo review. The boundary affects appellate strategy and reversal rates.
Rule 36 affirmances
The Federal Circuit's frequent use of one-line Rule 36 affirmances has been criticized for failing to provide reasoning, especially in PTAB appeals where the panel might have addressed novel statutory questions. The Supreme Court has thus far declined to take up direct challenges to the practice.
En banc rarity
The court grants en banc review infrequently, and several recurring questions — for example, the proper scope of inducement under § 271(b), or the correct framework for § 101 — have been pressed unsuccessfully. The grants that do come, however, often reshape the law substantially.
Standing in IPR appeals
The line between sufficient and insufficient injury for an unsuccessful IPR petitioner appellant continues to be litigated. Apple Inc. v. Qualcomm Inc., 992 F.3d 1378 (Fed. Cir. 2021), illustrates the narrowness of what survives.
Confidentiality and sealed appendices
The Federal Circuit has tightened rules on sealed materials in the joint appendix and briefs. Counsel must justify sealing every redaction with particular care.
See also
- Federal CircuitThe court itself — history, jurisdiction, and composition.
- Standards of reviewA more detailed treatment of de novo, clear error, substantial evidence, and abuse of discretion.
- Markman hearingsClaim construction, the central appellate issue, governed by Phillips and reviewed under Teva.
- Patent venueMandamus practice in the Federal Circuit on venue and transfer.
- Standing in patent casesArticle III standing for PTAB appeals.
- ITC Section 337 investigationsFederal Circuit appeals from ITC final determinations.
- Inter partes reviewPTAB proceedings appealed to the Federal Circuit.
- PTAB procedureThe Board procedures whose final decisions are reviewed.
- Phillips v. AWHA foundational en banc claim construction case.
- Octane Fitness v. ICONReviewed for abuse of discretion under Highmark.
- Halo v. PulseEnhanced damages reviewed for abuse of discretion.
- eBay v. MercExchangeInjunction grants and denials reviewed for abuse of discretion.
- GlossaryDefinitions of de novo, mandamus, en banc, and other appellate terms.
Last reviewed: 2026